JP2008526764A5 - - Google Patents

Download PDF

Info

Publication number
JP2008526764A5
JP2008526764A5 JP2007549646A JP2007549646A JP2008526764A5 JP 2008526764 A5 JP2008526764 A5 JP 2008526764A5 JP 2007549646 A JP2007549646 A JP 2007549646A JP 2007549646 A JP2007549646 A JP 2007549646A JP 2008526764 A5 JP2008526764 A5 JP 2008526764A5
Authority
JP
Japan
Prior art keywords
primary
epitope
mhc
immunogen
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007549646A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008526764A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/047442 external-priority patent/WO2006071990A2/en
Publication of JP2008526764A publication Critical patent/JP2008526764A/ja
Publication of JP2008526764A5 publication Critical patent/JP2008526764A5/ja
Pending legal-status Critical Current

Links

JP2007549646A 2004-12-29 2005-12-29 免疫応答の誘導におけるｃｄ４＋細胞の回避方法 Pending JP2008526764A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64082104P 2004-12-29 2004-12-29
PCT/US2005/047442 WO2006071990A2 (en) 2004-12-29 2005-12-29 Methods to bypass cd+4 cells in the induction of an immune response

Publications (2)

Publication Number Publication Date
JP2008526764A JP2008526764A (ja) 2008-07-24
JP2008526764A5 true JP2008526764A5 (enExample) 2009-02-26

Family

ID=36615526

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007549646A Pending JP2008526764A (ja) 2004-12-29 2005-12-29 免疫応答の誘導におけるｃｄ４＋細胞の回避方法

Country Status (9)

Country Link
US (1) US8703142B2 (enExample)
EP (1) EP1838342A2 (enExample)
JP (1) JP2008526764A (enExample)
AU (1) AU2005321905A1 (enExample)
CA (1) CA2592972A1 (enExample)
IL (1) IL184276A0 (enExample)
MX (1) MX2007008010A (enExample)
SG (1) SG158155A1 (enExample)
WO (1) WO2006071990A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977074B2 (en) * 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
EP2385059A3 (en) * 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
EP2023952B1 (en) 2006-05-18 2015-07-15 Epimmune Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2046344A2 (en) * 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
CN101657213B (zh) * 2007-02-15 2014-02-26 曼康公司 用于增强t细胞应答的方法
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
EP2152890A1 (en) * 2007-05-23 2010-02-17 MannKind Corporation Multicistronic vectors and methods for their design
WO2009003493A2 (en) 2007-07-03 2009-01-08 Dako Denmark A/S Mhc multimers, methods for their generation, labeling and use
WO2009039854A2 (en) 2007-09-27 2009-04-02 Dako Denmark A/S Mhc multimers in tuberculosis diagnostics, vaccine and therapeutics
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (en) 2008-07-23 2010-01-28 Dako Denmark A/S Combinatorial analysis and repair
GB0817244D0 (en) 2008-09-20 2008-10-29 Univ Cardiff Use of a protein kinase inhibitor to detect immune cells, such as T cells
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US20110195090A1 (en) * 2008-10-11 2011-08-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Method of making a vaccine
EP2490713A2 (en) 2009-10-23 2012-08-29 MannKind Corporation Cancer immunotherapy and method of treatment
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015199617A1 (en) * 2014-06-24 2015-12-30 National University Of Singapore A monoclonal antibody with t-cell receptor-like specificity that targets epstein-barr infected human tumour cells based on their expression of ebna1
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
TW201702272A (zh) * 2015-05-22 2017-01-16 美國紀念斯隆 凱特琳癌症中心 Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
WO2020127222A2 (en) 2018-12-17 2020-06-25 Immudex Aps Panel comprising borrelia mhc multimers

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
ES2265165T3 (es) * 1997-07-10 2007-02-01 Mannkind Corporation Dispositivo para inducir una respuesta ltc.
US6977074B2 (en) 1997-07-10 2005-12-20 Mannkind Corporation Method of inducing a CTL response
US6994851B1 (en) 1997-07-10 2006-02-07 Mannkind Corporation Method of inducing a CTL response
US20030138808A1 (en) 1998-02-19 2003-07-24 Simard John J.L. Expression vectors encoding epitopes of target-associated antigens
US6709844B1 (en) 2000-11-16 2004-03-23 Mannkind Corporation Avoidance of undesirable replication intermediates in plasmid propagation
US6656471B1 (en) 1998-11-17 2003-12-02 Board Of Regents, The University Of Texas System HIV-specific T-cell induction
CA2404041A1 (en) 2000-03-28 2001-10-04 The Regents Of The University Of California Methods for increasing a cytotoxic t lymphocyte response in vivo
US20030215425A1 (en) 2001-12-07 2003-11-20 Simard John J. L. Epitope synchronization in antigen presenting cells
CN1440462A (zh) 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
WO2002069907A2 (en) 2001-03-07 2002-09-12 Mannkind Corporation Anti-neovasculature preparations for cancer
WO2003008537A2 (en) 2001-04-06 2003-01-30 Mannkind Corporation Epitope sequences
MXPA04005382A (es) 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
EP1545610A4 (en) 2002-09-06 2006-11-08 Mannkind Corp EPITOPE SEQUENCES
US20050118186A1 (en) 2003-06-17 2005-06-02 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
JP5127224B2 (ja) * 2003-06-17 2013-01-23 マンカインド コーポレイション 予防又は治療目的のためのｍｈｃクラスｉ拘束性エピトープに対する免疫応答を誘発し、増強し、維持する方法
KR20070056042A (ko) 2004-06-17 2007-05-31 맨카인드 코포레이션 에피토프 유사체
US20050287068A1 (en) 2004-06-17 2005-12-29 Bot Adrian I Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods
US20060008468A1 (en) 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060159689A1 (en) 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
CA2592922A1 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs
WO2006071989A2 (en) 2004-12-29 2006-07-06 Mannkind Corporation Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU2005321898B2 (en) 2004-12-29 2012-07-19 Mannkind Corporation Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
EP2385059A3 (en) 2005-06-17 2012-02-15 Mannkind Corporation Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
US7511118B2 (en) 2005-06-17 2009-03-31 Mannkind Corporation PSMA peptide analogues
NZ587601A (en) 2005-06-17 2012-05-25 Mannkind Corp Multivalent Entrain-and-Amplify Immunotherapeutics for Carcinoma
EP2046344A2 (en) 2006-07-14 2009-04-15 MannKind Corporation Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes

Similar Documents

Publication Publication Date Title
Barnett et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
Corey et al. Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen
Cristillo et al. Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations
Goepfert et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects
Jiang et al. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides
Fast et al. Human trials of experimental AIDS vaccines
Zolla-Pazner et al. Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines
US8338582B2 (en) Anti-HIV immunogens and methods for inducing an immune response
Koff et al. Human trials of AIDS vaccines: current status and future directions
Flynn et al. Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination
Launay et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
Flynn et al. Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain
Kumar et al. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses
Edgeworth et al. Vaccine development against HIV-1: current perspectives and future directions
Stott Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines
Lockey et al. Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees
AU2004269379A1 (en) Immunogenic HIV compositions and related methods
Tramont et al. Progress in the development of an HIV vaccine
Temchura et al. The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!
Mohan et al. Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides
Bazhan et al. A synergistic effect of a combined bivalent DNA–protein anti-HIV-1 vaccine containing multiple T-and B-cell epitopes of HIV-1 proteins
Silvera et al. Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques
Ruffin et al. Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011
CN107224578B (zh) Hiv疫苗及其制备方法
Seo et al. Marked enhancement of neutralizing antibody and IFN-γ T-cell responses by GX-19N DNA booster in mice primed with inactivated vaccine